eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
abstract:
Original paper

The crosstalk effect of cancer stem cells in the progression of pediatric medulloblastoma through signaling expression of CD133, CD44, and OCT4 with and without Wnt-b-catenin activation

Maher Kurdi
1
,
Alaa Alkhotani
2
,
Motaz Fadul
1
,
Huda Alghefari
1
,
Awab T. Tayyib
3
,
Thamer Alsharif
4
,
Majid Almansouri
5
,
Yazid Maghrabi
6
,
Shadi Alkhayyat
7
,
Taghreed Alsinani
8
,
Ahmed K. Bamaga
9
,
Saleh Baeesa
6

  1. Department of Pathology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia
  2. Department of Pathology, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
  3. Department of Pathology, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia
  4. Department of Surgery, King Abdulaziz Specialist Hospital, Taif, Saudi Arabia
  5. Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
  6. Department of Neurosciences, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
  7. Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
  8. Department of Neurosurgery, King Fahad General Hospital, Jeddah, Saudi Arabia
  9. Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Folia Neuropathol 2024; 62 (4)
DOI: https://doi.org/10.5114/fn.2024.144903
Online publish date: 2024/11/20
View full text Get citation
 
PlumX metrics:
Introduction:
Cancer stem cells (CSCs) are principal drivers in medulloblastoma (MB) initiation, growth, and progression. Our study aimed to explore the expression of CD133, CD44, and OCT4 signaling markers and their effects on the progression of MB.

Material and methods:
A retrospective cohort analysis was conducted on brain tissue of 24 pediatric cases of MB from 2016-2020. Protein expression levels of CSC markers CD133, CD44, and OCT4 were evaluated immunohistochemically and their correlation with b-catenin activity was statistically analyzed.

Results:
The mean age of patients was 10.2 years (range 3-17), with 18 (75%) males and 6 (25%) females. b-catenin was expressed in 20 (83.3%) tumors, and 4 (16.7%) tumors showed no expression. CD133 was minimally expressed in 6 (25%) tumors and 18 tumors (75%) showed no expression. CD44 was highly expressed in 6 (25%) tumors and 18 (75%) tumors showed minimal to no expression. OCT4 was expressed in all tumors. Despite MBs with positive b-catenin expression and absent CD133 expression having longer progression-free survival (PFS), this impact on PFS did not reach statistical significance (p = 0.76). However, statistically significant differences in PFS were observed in MBs with positively expressed b-catenin and minimal or no CD44 expression, which showed prolonged PFS (p = 0.0064). MB patients who did not express CD133 and received combined radiotherapy (RTx) and chemotherapy (CTx) showed longer PFS compared to MB patients with minimal CD133 expression. However, this association was statistically insignificant (p = 0.42). The impact of CD44 expression and chemoradiation on PFS was statistically significant (p = 0.0035). MB patients with absent or minimal CD44 expression who received RTx and CTx showed the longest PFS.

Conclusions:
Medulloblastomas not expressing CSC markers (CD133, CD44) are associated with prolonged PFS and less resistance to chemoradiation. However, b-catenin is considered the main predictor for prognosis when compared to CSC markers.

keywords:

medulloblastoma, cancer stem cells, CD133, CD44, OCT4, prognosis
FEATURED PRODUCTS
BOOKS
• Wprowadzenie do neurologopedii Wydanie II zaktualizowane
EVENTS
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.